Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastrointestinal Neuroendocrine Carcinoma”

561 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 561 results

Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Study completedNCT00002608
What this trial is testing

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Who this might be right for
Adrenocortical CarcinomaBrain and Central Nervous System TumorsHead and Neck Cancer+4 more
Ottawa Regional Cancer Centre 30
Early research (Phase 1)UnknownNCT02457650
What this trial is testing

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Who this might be right for
Bladder CarcinomaBreast CancerEsophagus Carcinoma+7 more
Shenzhen Second People's Hospital 36
Early research (Phase 1)Ended earlyNCT05573035
What this trial is testing

Investigate LYL845 in Adults With Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerColorectal Cancer
Lyell Immunopharma, Inc. 39
Testing effectiveness (Phase 2)WithdrawnNCT06090318
What this trial is testing

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Who this might be right for
Advanced Solid TumorCDKN2ANSCLC+7 more
Rain Oncology Inc
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Early research (Phase 1)Ended earlyNCT05061537
What this trial is testing

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Who this might be right for
Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more
Pfizer 13
Early research (Phase 1)Study completedNCT01625351
What this trial is testing

CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Who this might be right for
Ewing SarcomaGastrointestinal TumorGerm Cell Tumor+10 more
St. Jude Children's Research Hospital 23
Early research (Phase 1)Study completedNCT00405587
What this trial is testing

Safety Study of PLX4032 in Patients With Solid Tumors

Who this might be right for
Malignant MelanomaColorectal Carcinoma
Plexxikon 109
Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Early research (Phase 1)Ended earlyNCT05576077
What this trial is testing

TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerColorectal CancerUveal Melanoma+3 more
Turnstone Biologics, Corp. 31
Not applicableNo Longer AvailableNCT01980732
What this trial is testing

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Who this might be right for
Carcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors
Andrei Iagaru
Testing effectiveness (Phase 2)Study completedNCT05864144
What this trial is testing

SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultAdvanced Solid TumorHead and Neck Cancer+19 more
Sensei Biotherapeutics, Inc. 98
Testing effectiveness (Phase 2)Looking for participantsNCT03412877
What this trial is testing

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Who this might be right for
Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer+4 more
National Cancer Institute (NCI) 285
Testing effectiveness (Phase 2)UnknownNCT04913337
What this trial is testing

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
MesotheliomaGlioblastomaRenal Cell Carcinoma+12 more
NGM Biopharmaceuticals, Inc 179
Early research (Phase 1)Looking for participantsNCT07106827
What this trial is testing

GV20-0251 in Advanced or Refractory Solid Tumors

Who this might be right for
HCC - Hepatocellular CarcinomaCholangiocarcinomaMelanoma+5 more
West China Hospital 10
Early research (Phase 1)Study completedNCT00667641
What this trial is testing

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Who this might be right for
Breast CancerColorectal CancerHead and Neck Cancer+6 more
University of Medicine and Dentistry of New Jersey 16
Testing effectiveness (Phase 2)Ended earlyNCT01056601
What this trial is testing

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Who this might be right for
Pancreatic Cancer
Masonic Cancer Center, University of Minnesota 7
Early research (Phase 1)Study completedNCT01048892
What this trial is testing

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Who this might be right for
Adrenocortical CarcinomaGastrointestinal Carcinoid TumorKidney Cancer+3 more
Children's Oncology Group 22
Not applicableNot Yet RecruitingNCT07689812
What this trial is testing

Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)+12 more
Natera, Inc. 920
Next Page